Skip to main content

LIVN

Stock
Health Care
Medical Devices

Performance overview

LIVN Price
Price Chart

Forward-looking statistics

Beta
1.18
Risk
38.80%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.

Company info

SectorHealth Care
IndustryMedical Devices
Employees3K
Market cap$2.9B

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+0.2
Credit+5.2
Liquidity-0.3
Inflation-3.0
Commodities-0.5
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio12.13
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.

Zacks Investment Research (May 7, 2025)
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.

Benzinga (October 4, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free